
Beyond The Price Tag: The Dark Side Of Luxury And Circular Fashion
Luxury fashion has long positioned itself as an exclusive alternative to fast fashion, with brands like Louis Vuitton, Chanel and Christian Dior boasting craftsmanship and heritage. However, luxury is not without its sustainability challenges. Meanwhile, the fashion resale and clothing rental models are gaining traction, offering potential solutions to the industry's overproduction crisis. According to ThredUp, the global secondhand market is projected to reach $350 billion by 2027, signaling a shift in consumer preferences.
Luxury brands emphasize exclusivity, but their supply chains remain opaque. The use of exotic materials, such as crocodile leather and mink fur, raises ethical concerns, while some brands destroy unsold inventory to maintain brand value. According to research by Dr. Hakan Karaosman, the luxury fashion market reached an estimated €1.2 trillion globally in 2018, with the personal luxury goods sector—including apparel, textiles, and footwear—growing to €260 billion, reflecting a 6% increase. Despite luxury brands' reputation for high-quality, durable materials, they drive relentless consumer demand through capsule collections and celebrity-endorsed limited editions.
However, the industry's environmental and social costs are substantial. According to NGOs and consumer groups, luxury fashion brands have been linked to burning excess stock, polluting with hazardous chemicals, excessive water consumption, and exploiting labor while falsely marketing products as 'Made in Italy'. Additionally, automation, shifting ownership norms, and increasing transparency demands have left luxury fashion leaders grappling with tough challenges in an evolving marketplace.
According to a 2018 Burberry report, the brand incinerated over $36 million worth of unsold products in one year alone, highlighting the industry's hidden waste problem. The brand explained that the items were destroyed to prevent them from being sold at a discount. It emphasized taking waste management 'extremely seriously' and claimed to use special incinerators to generate energy from the process.
Platforms like ThredUp, The Thrift Hub in Jamaica and Depop are redefining fashion consumption by extending the lifespan of garments. According to Eco Cart, buying secondhand reduces a garment's carbon footprint by 82% compared to buying new. Additionally, sustainable fashion is rapidly gaining momentum. Statista reports that the global sustainable apparel market is projected to grow from $6.3 billion in 2023 to $12.6 billion by 2030. However, high-end resale platforms still contribute to overconsumption by marketing secondhand shopping as an endless cycle of buying and reselling.
Rental services like Rent the Runway promote access over ownership, reducing demand for single-use purchases. However, the model is not without flaws—constant shipping, dry cleaning, and packaging generate emissions that sometimes offset its benefits.
According to researchers at Finland's LUT University, renting clothing—where a single garment is leased to multiple users—may be less sustainable than expected. A study published in the Finnish scientific journal Environmental Research Letters found that renting fashion can generate more global warming emissions than simply discarding garments. The research, highlights that the environmental cost of rental fashion stems from transportation emissions. The model assumes that consumers travel at least two kilometers to return rented jeans, and after ten uses, they exchange them for a new pair—leading to increased carbon footprints primarily due to vehicle emissions.
The fashion industry's business models—whether fast fashion, luxury, resale, or rental—are driving overconsumption, supply chain inefficiencies, and unsustainable labor practices. Luxury fashion, despite its craftsmanship and exclusivity, relies on limited-edition collections and high turnover, fueling relentless demand. Fast fashion accelerates waste and exploits garment workers, while ultra-fast fashion takes this to extreme levels, producing thousands of new styles daily. Resale platforms, while extending garment lifespans, still encourage continuous buying and selling. Rental fashion, once considered a circular solution, has hidden sustainability drawbacks, including emissions from transportation and cleaning. Ultimately, these business models prioritize profit over ethical supply chains, often leaving workers without a livable wage and pushing environmental costs onto society. The solution lies in systemic change—brands must shift from volume-driven profits to responsible production, fair wages, and transparent sourcing. Consumers must also challenge the narrative of endless newness and embrace true sustainability over performative greenwashing. Read our previous article Beyond The Price Tag: The Dark Side Of Fast Fashion Business Models, and stay tuned as our series continues with an in-depth examination of fashion's pollution problem.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Insider
3 hours ago
- Business Insider
A Hugging Face research scientist is in talks to raise around $40 million for a buzzy robotics startup, sources say
The robotics lead at open-source AI company Hugging Face is in talks to raise funding for his own robotics startup, Business Insider has learned. Remi Cadene's startup, Uma, is in discussions to raise around $40 million in seed funding, two sources told Business Insider. There is no public information about Cadene's Paris-based startup, but one source said it's working on full-stack robotics for industrial and commercial use cases. Cadene is a robotics research veteran who has previously worked for Meta and Tesla. During his most recent stint at Tesla, he was a staff scientist working in its humanoid robot and self-driving divisions. He is now a principal research scientist at Hugging Face, which he joined in March 2024. Four sources confirmed the existence of Uma to Business Insider. There is no reference to Cadene's startup on his LinkedIn profile or personal website, suggesting the startup is still in stealth mode. Cadene's "scientific interest lies in understanding the underlying mechanisms of intelligence," according to his blog. Details about Uma's round size and deal are subject to change as the deal has not been finalized yet. Hugging Face and Cadene did not respond to Business Insider's requests for comments. Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. What is your job title? (1 of 2) Entry level position Project manager Management Senior management Executive management Student Self-employed Retired Other Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . The hype around AI has galvanized investor interest in robotics, with startups globally raising $17.2 billion in 2024. This year, momentum for the technology has been strong, with robotics startups raising over $16 billion in 2025 so far, per PitchBook data. Notable raises this year include Genesis Robotics' $110 million seed round and Coco Robotics' $80 million round. Hugging Face has also dabbled in the robotics sector, recently launching a desktop robot after acquiring Pollen Robotics in 2025. Larger AI companies have long been founder factories for executives and researchers. This week, GitHub CEO Thomas Dohmke announced that he would be exiting the developer platform to become a startup founder again.
Yahoo
8 hours ago
- Yahoo
Norgine completes acquisition of Theravia
PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions. The closure of this acquisition marks a major step forward for Norgine to deliver on its ambition to bring life-changing medicines to patients with high unmet medical needs. With the transaction now complete, Norgine will begin a structured integration process to align operations, systems, and teams. "We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in, and growing portfolio of rare disease medicines," said Janneke van der Kamp, Chief Executive Officer, Norgine. "This acquisition marks a critical step forward in our growth strategy, and with our strong focus on expanding the reach of products to patients in areas of high unmet medical need in Europe and ANZ, we are well positioned to ensure Theravia's medicines will reach more patients." As a result of the acquisition, Theravia has become a wholly owned subsidiary of Norgine. Notes About Norgine Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €550 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand. Norgine's integrated approach – strong commercial capabilities, as well as deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures that Norgine can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually. Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into therapeutic innovation. NORGINE and the sail logo are trademarks of the Norgine group of companies. Logo: Media contact: Annabel Cowperacowper1@ View original content: SOURCE Norgine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation to investigational therapies addressing rare, life-threatening or debilitating medical diseases or conditions that affect no more than 5 in 10,000 persons in the EU. Rilzabrutinib for the treatment of IgG4-related disease was evaluated in a phase 2 study (clinical study identifier: NCT04520451) and results were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress. In IgG4-RD patients, treatment with rilzabrutinib for 52 weeks led to reduction in disease flare, other disease markers, and glucocorticoid sparing. The safety profile of rilzabrutinib in the study was consistent with previous studies, with no new safety signals observed. In addition to IgG4-related disease, rilzabrutinib has received orphan designations for immune thrombocytopenia (ITP) in the US, the EU, and Japan; and for warm autoimmune hemolytic anemia, IgG4-RD and sickle cell disease in the US. Rilzabrutinib has also been granted fast track designation in the US in ITP and IgG4-RD. Rilzabrutinib is currently under regulatory review in the US, the EU, and China for its potential use in ITP. The target action date for the US FDA regulatory decision for ITP, which was granted fast track designation, is August 29, 2025. Rilzabrutinib is an investigational agent, and its safety and efficacy have not been evaluated by any regulatory authority. About rilzabrutinib Rilzabrutinib is a novel, advanced, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side IgG4-RD IgG4-RD is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes-fatal outcome. People with IgG4-RD experience frequent flare-ups of the condition characterized by periods of exacerbated symptoms. It affects approximately eight out of 100,000 adult patients in the US each year. Due to its rarity and challenges with diagnosis, the global prevalence of IgG4-RD is unknown. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data